Trailing the Big Pharma players, a lesser known BCMA CAR-T candidate comes into the spotlight
Bristol Myers Squibb and bluebird cleared the first BCMA CAR-T therapy for multiple myeloma patients back in March, and J&J and their partners at Legend Biotech aren’t far behind. Now, a lesser known candidate developed in China is coming into the spotlight at EHA.
IBI326, a BCMA CAR-T therapy developed by Innovent Biologics and IASO Biotherapeutics, had a 97.1% overall response rate in 35 patients with relapsed or refractory multiple myeloma, according to updated Phase I data the companies are taking to EHA. IASO CEO Maxwell Wang says it’s the only oral presentation on a Chinese BCMA CAR-T at this year’s conference.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.